352 related articles for article (PubMed ID: 28257090)
1. From General Aberrant Alternative Splicing in Cancers and Its Therapeutic Application to the Discovery of an Oncogenic DMTF1 Isoform.
Tian N; Li J; Shi J; Sui G
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257090
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin sensitivity in breast cancer cells is associated with particular DMTF1 splice variant expression.
Niklaus NJ; Humbert M; Tschan MP
Biochem Biophys Res Commun; 2018 Sep; 503(4):2800-2806. PubMed ID: 30100063
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms regulating DMTF1β/γ expression and their functional interplay with DMTF1α.
Li J; Shi K; Xu T; Hu J; Li T; Li G; Chen K; Li D; Inoue K; Sui G
Int J Oncol; 2021 Jan; 58(1):20-32. PubMed ID: 33367929
[TBL] [Abstract][Full Text] [Related]
4. RNA binding protein RALY promotes Protein Arginine Methyltransferase 1 alternatively spliced isoform v2 relative expression and metastatic potential in breast cancer cells.
Bondy-Chorney E; Baldwin RM; Didillon A; Chabot B; Jasmin BJ; Côté J
Int J Biochem Cell Biol; 2017 Oct; 91(Pt B):124-135. PubMed ID: 28733251
[TBL] [Abstract][Full Text] [Related]
5. DMP1β, a splice isoform of the tumour suppressor DMP1 locus, induces proliferation and progression of breast cancer.
Maglic D; Stovall DB; Cline JM; Fry EA; Mallakin A; Taneja P; Caudell DL; Willingham MC; Sui G; Inoue K
J Pathol; 2015 May; 236(1):90-102. PubMed ID: 25537728
[TBL] [Abstract][Full Text] [Related]
6. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
[TBL] [Abstract][Full Text] [Related]
7. Alternative splicing: an emerging topic in molecular and clinical oncology.
Pajares MJ; Ezponda T; Catena R; Calvo A; Pio R; Montuenga LM
Lancet Oncol; 2007 Apr; 8(4):349-57. PubMed ID: 17395108
[TBL] [Abstract][Full Text] [Related]
8. ELF5 isoform expression is tissue-specific and significantly altered in cancer.
Piggin CL; Roden DL; Gallego-Ortega D; Lee HJ; Oakes SR; Ormandy CJ
Breast Cancer Res; 2016 Jan; 18(1):4. PubMed ID: 26738740
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis.
Wali VB; Gilmore-Hebert M; Mamillapalli R; Haskins JW; Kurppa KJ; Elenius K; Booth CJ; Stern DF
Breast Cancer Res; 2014 Dec; 16(6):501. PubMed ID: 25516216
[TBL] [Abstract][Full Text] [Related]
10. CD44 alternative splicing and hnRNP A1 expression are associated with the metastasis of breast cancer.
Loh TJ; Moon H; Cho S; Jang H; Liu YC; Tai H; Jung DW; Williams DR; Kim HR; Shin MG; Liao DJ; Zhou J; Shi W; Zheng X; Shen H
Oncol Rep; 2015 Sep; 34(3):1231-8. PubMed ID: 26151392
[TBL] [Abstract][Full Text] [Related]
11. A method for identifying discriminative isoform-specific peptides for clinical proteomics application.
Zhang F; Chen JY
BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):522. PubMed ID: 27557076
[TBL] [Abstract][Full Text] [Related]
12. An alternative splicing isoform of eukaryotic initiation factor 4H promotes tumorigenesis in vivo and is a potential therapeutic target for human cancer.
Wu D; Matsushita K; Matsubara H; Nomura F; Tomonaga T
Int J Cancer; 2011 Mar; 128(5):1018-30. PubMed ID: 20473909
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers.
Sahin I; George A; Seyhan AA
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769221
[TBL] [Abstract][Full Text] [Related]
14. Alternative splicing in cancers: From aberrant regulation to new therapeutics.
Song X; Zeng Z; Wei H; Wang Z
Semin Cell Dev Biol; 2018 Mar; 75():13-22. PubMed ID: 28919308
[TBL] [Abstract][Full Text] [Related]
15. Alternative RNA Splicing-The Trojan Horse of Cancer Cells in Chemotherapy.
Mehterov N; Kazakova M; Sbirkov Y; Vladimirov B; Belev N; Yaneva G; Todorova K; Hayrabedyan S; Sarafian V
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356101
[TBL] [Abstract][Full Text] [Related]
16. Alternative Splicing in Adhesion- and Motility-Related Genes in Breast Cancer.
Aversa R; Sorrentino A; Esposito R; Ambrosio MR; Amato A; Zambelli A; Ciccodicola A; D'Apice L; Costa V
Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26784191
[TBL] [Abstract][Full Text] [Related]
17. Aberrant splicing, hyaluronan synthases and intracellular hyaluronan as drivers of oncogenesis and potential drug targets.
Adamia S; Pilarski PM; Belch AR; Pilarski LM
Curr Cancer Drug Targets; 2013 May; 13(4):347-61. PubMed ID: 23517594
[TBL] [Abstract][Full Text] [Related]
18. PCBP1 inhibits the expression of oncogenic STAT3 isoform by targeting alternative splicing of STAT3 exon 23.
Wang X; Guo J; Che X; Jia R
Int J Biol Sci; 2019; 15(6):1177-1186. PubMed ID: 31223278
[TBL] [Abstract][Full Text] [Related]
19. Sequence, "subtle" alternative splicing and expression of the CYYR1 (cysteine/tyrosine-rich 1) mRNA in human neuroendocrine tumors.
Vitale L; Frabetti F; Huntsman SA; Canaider S; Casadei R; Lenzi L; Facchin F; Carinci P; Zannotti M; Coppola D; Strippoli P
BMC Cancer; 2007 Apr; 7():66. PubMed ID: 17442112
[TBL] [Abstract][Full Text] [Related]
20. CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion.
Tien JF; Mazloomian A; Cheng SG; Hughes CS; Chow CCT; Canapi LT; Oloumi A; Trigo-Gonzalez G; Bashashati A; Xu J; Chang VC; Shah SP; Aparicio S; Morin GB
Nucleic Acids Res; 2017 Jun; 45(11):6698-6716. PubMed ID: 28334900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
